An interventional study of Hyaluronic Acid Complex and Dexamethasone in Postoperative Morbidity, sponsored by Cyprus Health and Social Sciences University. Completed at 1 site in Cyprus. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Cyprus Health and Social Sciences University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies testing dexamethasone in Pain, Postoperative — 27 open to participants now, 31 under way, 2 of them phase 3. Dexamethasone · Pain, Postoperative.
Among the 149 studies testing dexamethasone in Pain, Postoperative, this one is the 131st largest by enrollment, is one of 17 that started in 2026, is one of 38 with no phase, and was the 146th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →27 of the 149 studies testing dexamethasone in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 50–70
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–79
Marmara University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 18–65
Oman Ministry of Health · Sites in Oman
Ages 21–80
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 14 · Phase 3 19 · Phase 4 75
First in 2005; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 88 across the 149 interventional studies. Of the 96 that completed or were terminated, 22 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 149 have an industry lead sponsor. The 10 most frequent:
Cyprus Health and Social Sciences University is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Cyprus Health and Social Sciences University has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
11 of the studies testing dexamethasone in Pain, Postoperative that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07847047Phase 3Assiut UniversitySafety and Efficacy of Dexamethasone Versus Dexmedetomidine as Adjuvants in PENG Block in Hip Surgeries for Postoperative Pain Management | 2027-10 |
| NCT07795281Gaziantep City HospitalIntravenous Dexamethasone Added to Dexmedetomidine After Superior Trunk Block | 2026-12 |
| NCT07380139Ain Shams UniversityDexamethasone vs Dexmedetomidine in Sphenopalatine Ganglion Block for Rhinoplasty Pain | 2026-12-01 |
| NCT07672873Marmara UniversityLocal Dexamethasone Administration in Symptomatic Irreversible Pulpitis | 2026-12-15 |
| NCT07099222University of ArizonaEfficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 149 studies testing dexamethasone in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aimed to comparatively evaluate the effects of a hyaluronic acid complex and dexamethasone on postoperative pain, swelling, and trismus following mandibular third molar surgery, compared with a control group. Participants were evaluated in three groups: a hyaluronic acid complex group, a dexamethasone group, and a control group. Postoperative pain, facial swelling, and limitation of mouth opening were assessed during the postoperative follow-up period to compare postoperative outcomes among the groups.
The criteria were revised on the registry on Oct 6, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Following mandibular third molar extraction, SPONGOSTAN™ Dental absorbable hemostatic gelatin sponge (MS0005; 1 × 1 × 1 cm; Ethicon, Johnson \& Johnson) was placed into the extraction socket. No hyaluronic acid complex or dexamethasone was administered. The surgical site was primarily closed with 3/0 silk sutures, which were removed on postoperative day 7.
Device: Absorbable Hemostatic Gelatin Sponge (SPONGOSTAN™ Dental)
Following mandibular third molar extraction, 0.2 mL of Monovisc® (22 mg/mL cross-linked high-molecular-weight sodium hyaluronate; Anika Therapeutics, Inc., Bedford, MA, USA), corresponding to 4.4 mg of sodium hyaluronate, was applied directly into the extraction socket. SPONGOSTAN™ Dental was subsequently placed to enhance retention within the socket. The surgical site was primarily closed with 3/0 silk sutures, which were removed on postoperative day 7.
Drug: Hyaluronic Acid Complex · Device: Absorbable Hemostatic Gelatin Sponge (SPONGOSTAN™ Dental)
Following mandibular third molar extraction, 1.5 mL of DEKORT® 8 mg/2 mL I.M./I.V. solution for injection (DEVA Holding A.Ş., Türkiye), corresponding to 6 mg of dexamethasone, was absorbed into SPONGOSTAN™ Dental and placed into the extraction socket. The surgical site was primarily closed with 3/0 silk sutures, which were removed on postoperative day 7.
Drug: Dexamethasone · Device: Absorbable Hemostatic Gelatin Sponge (SPONGOSTAN™ Dental)
Monovisc® (Anika Therapeutics, Inc., Bedford, MA, USA), containing 22 mg/mL cross-linked, high-molecular-weight sodium hyaluronate, was used. A 0.2 mL volume of the preparation (equivalent to 4.4 mg sodium hyaluronate) was applied directly into the extraction socket using a sterile applicator. SPONGOSTAN™ Dental absorbable hemostatic gelatin sponge was subsequently placed into the socket to enhance retention of the preparation.
DEKORT® 8 mg/2 mL solution for I.M./I.V. injection (DEVA Holding A.Ş., Türkiye) was used. A 1.5 mL volume of the solution, corresponding to 6 mg dexamethasone, was absorbed into a SPONGOSTAN™ Dental absorbable hemostatic gelatin sponge and placed directly into the extraction socket.
SPONGOSTAN™ Dental absorbable hemostatic gelatin sponge (MS0005; 1 × 1 × 1 cm; Ethicon, Johnson \& Johnson) was placed directly into the extraction socket. In the control group, the gelatin sponge was used without hyaluronic acid or dexamethasone.
Postoperative Pain Assessed Using the Visual Analog Scale (VAS)
Postoperative pain was assessed using a patient-reported Visual Analog Scale (VAS) ranging from 0 to 10, where 0 indicated no pain and 10 indicated unbearable/worst pain. Participants indicated their perceived pain intensity on the scale. No preoperative VAS measurement was performed
Time frame: Postoperative days 1, 2, 3, and 7
Facial Swelling Assessed Using Facial Measurements
Facial swelling was assessed in millimeters (mm) using a flexible measuring tape. Three anatomical distances were measured: tragus to labial commissure, tragus to pogonion, and mandibular angle to lateral canthus. The arithmetic mean of the three measurements was calculated for each participant. Postoperative percentage change from the preoperative baseline was calculated as \[(postoperative mean - preoperative mean) / \|preoperative mean\|\] × 100. Positive values indicated an increase in facial measurements.
Time frame: Preoperatively and on postoperative days 1, 2, 3, and 7
Trismus Assessed by Maximum Interincisal Mouth Opening
Trismus was assessed by measuring maximum interincisal mouth opening in millimeters (mm) using a digital caliper. The distance between the incisal edges of the maxillary and mandibular central incisors was measured once at each assessment. Postoperative percentage change from the preoperative baseline was calculated as \[(postoperative value - preoperative value) / \|preoperative value\|\] × 100. Negative values indicated a reduction in maximum mouth opening.
Time frame: Preoperatively and on postoperative days 1, 2, 3, and 7
Plan to share: No — Individual participant data will not be shared, as no IPD sharing plan was established for this study.
No publications or documents are linked to this record.
Ran from Mar 2026 to primary completion in Jul 2026, 4 months.
Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 4 months is below that.
Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone
Cyprus Health and Social Sciences University